The short answer
Mesothelioma does not have its own SEER stat-facts page, so this uses the American Cancer Society's analysis of SEER data for pleural mesothelioma (the most common type), diagnosed 2015–2021. Overall five-year relative survival is 15%, ranging from 23% for localized disease to 11% for distant disease.
A survival statistic describes a large group diagnosed years ago — not a prediction for any one person.
For pleural mesothelioma, the five-year relative survival rate for everyone combined, diagnosed 2015–2021, was 15%.
Stage at diagnosis makes a large difference: localized disease is 23% versus 11% for distant (metastatic) disease.
Mesothelioma is rare enough that SEER does not publish its own dedicated statistics page; these figures come from the American Cancer Society's analysis of SEER data.
Choose how you want to understand this
The full explanation.
Before you look at the numbers
Three things are true about the numbers below. Please read all three before you look at a single mesothelioma percentage.
First, a "5-year relative survival rate" for mesothelioma describes a large group of people. Those people were diagnosed with pleural mesothelioma years ago. It is not a prediction about you. Everyone's mesothelioma, body, and treatment plan are different.
Second, this data lags behind today's care. These figures reflect people diagnosed between 2015 and 2021. Mesothelioma often is not found until years or decades after asbestos exposure. Treatment has kept changing since this group was diagnosed, including immunotherapy combinations. So mesothelioma treatment today may already work better than these numbers suggest.
Third, an all-stages mesothelioma number blends two very different groups. It mixes people whose mesothelioma was found early. It also counts people whose mesothelioma had already spread. For mesothelioma, the stage-specific numbers below beat one blended average. And "5-year" is just a measuring window, not a mesothelioma milestone. It is not a life expectancy for anyone with mesothelioma. It is not a deadline either.
The SEER numbers for pleural mesothelioma
Mesothelioma is rare. SEER does not publish its own statistics page for it. More common cancers each get one. So these figures come from the American Cancer Society. It uses the same SEER data. They cover people diagnosed between 2015 and 2021 with pleural mesothelioma. That is the type in the lining of the lungs, and it is the most common. For that group, the overall five-year relative survival rate is 15%.
These figures cover pleural mesothelioma only. That type makes up more than 8 in 10 mesotheliomas. Peritoneal mesothelioma grows in the lining of the belly. It is tracked on its own, and it is not included here.
| Stage at diagnosis | 5-year relative survival |
|---|---|
| Localized — confined to the point where it started | 23% |
| Regional — spread to nearby tissue | 15% |
| Distant — spread to other parts of the body | 11% |
| All SEER stages combined | 15% |
What "relative survival" actually means
Relative survival compares two groups. One group has pleural mesothelioma. The other group is the same age and sex, but has no mesothelioma. Say the rate is 100%. That would mean the mesothelioma group was as likely to reach 5 years as the other. It is not the share of people who are free of mesothelioma. It is not the share of people who die from mesothelioma itself.
In mesothelioma, the outlook depends heavily on histologic subtype. That means the kind of cell the tumor is made of. Epithelioid mesothelioma is the most common subtype and the slowest growing. It generally has a better outlook than the sarcomatoid or mixed (biphasic) subtypes. Whether surgery can remove the tumor also plays a large role. The same is true of other cancers found in the chest or belly.
What actually changes your outlook
A statistic describes a group. Your outlook depends on things specific to you.
- Stage — how far the mesothelioma has spread, as shown in the table above.
- Grade — how odd the mesothelioma cells look, and how fast they tend to grow.
- Histologic subtype — epithelioid, sarcomatoid, and biphasic (mixed) mesothelioma have different outlooks. Epithelioid is generally the most favorable.
- Resectability — whether surgery can remove some or all of the tumor.
- How your mesothelioma responds — early scans and labs often say more than the first numbers.
- Your overall health — other health problems, age, and fitness shape mesothelioma treatment and recovery.
- Access to care — a quick mesothelioma diagnosis, specialist care, and finishing treatment all matter.
Questions for your care team
- Which SEER stage describes my mesothelioma, and what is its five-year number?
- Which biomarkers or molecular tests matter in mesothelioma, and were they run on my sample?
- How do my age and overall health change these mesothelioma statistics for me?
- Are there newer mesothelioma treatments available now that this data doesn't reflect yet?
- Beyond the general mesothelioma statistics, what does my team expect in my case?
- Where can I find support for how it feels to hear these mesothelioma numbers?
- Is my mesothelioma pleural or peritoneal? Which subtype is it: epithelioid, sarcomatoid, or biphasic?
If these numbers are hard to sit with
Mesothelioma numbers can leave you scared, numb, or overwhelmed. That is normal. It does not mean you are handling a mesothelioma diagnosis the wrong way. Many people take these mesothelioma numbers in slowly, or with someone in the room. Others skip the numbers until they feel ready. Cancer Anxiety and Uncertainty covers the fear these mesothelioma numbers can stir up. It is also worth telling your mesothelioma team how much detail you want, and when.
Sources
Words to know
Tap any term to see what it means.
Common questions
What does 15% five-year relative survival mean for pleural mesothelioma?
It means that, on average, people diagnosed with pleural mesothelioma between 2015 and 2021 were about 15% as likely to be alive 5 years later as people of the same age and sex without pleural mesothelioma. It blends every stage together, from early to advanced.
Why is the stage-specific number so different from the overall number?
The overall number blends people found early, when pleural mesothelioma is most treatable, with people found later. Stage makes a large difference — see the table above. Localized pleural mesothelioma usually has a much higher five-year relative survival than distant (metastatic) disease.
Does this number predict what will happen to me?
No. This is a statistic about a large group of people, not a prediction about you. Your age, overall health, tumor biology, and how your pleural mesothelioma responds to treatment all shape your individual outlook in ways a group statistic cannot capture.
Is this the most current data available?
It is the most recent mesothelioma data available. SEER has no stat facts page for mesothelioma, so the cohort here is the American Cancer Society's choice, not SEER's: people diagnosed between 2015 and 2021. Where SEER does publish its own pages, they have moved on to people diagnosed between 2016 and 2022. Treatments keep changing, so people diagnosed today may do better than these numbers suggest.
Why doesn't SEER have its own statistics page for mesothelioma?
Mesothelioma is rare, and SEER's individual 'Cancer Stat Facts' pages are generally reserved for more common cancer types. SEER still collects mesothelioma data, and organizations like the American Cancer Society use that same underlying SEER data to publish mesothelioma-specific survival statistics, which is the source used on this page.
Why is 'regional' mesothelioma survival (15%) about the same as the overall rate?
This reflects real variation in a fairly small dataset, since mesothelioma is uncommon. It's a reminder that these percentages are estimates from limited numbers of people, with more statistical noise than figures for common cancers like breast or lung cancer.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Last updated: 2026-08-19Next planned review: 2027-08-03
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
High-risk topic — talk to your care team. This topic can involve urgent, individual medical decisions. This page is general education only: it cannot tell you whether your situation is an emergency or what you personally should do. Follow your oncology team's instructions and contact them for individual guidance.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share